The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
China’s healthcare sector kept growing over the second quarter of 2019. The period was characterised by increased government spending on healthcare, with the amount dedicated to health and family planning rising by 5.9% y/y to RMB 534.5bn in Q2 ...View more details
The first quarter of 2019 witnessed a continuous growth of China’s healthcare sector. The country promoted the implementation of the Healthy China Initiative, as well as ongoing structural reforms in the sector. The period was characterized by ...View more details
China’s healthcare sector continued to grow in Q4 2018, largely stimulated by the expansion of online healthcare services. The growth was attributed to increasing demand for quality healthcare, driven by the country’s strong economic ...View more details
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...View more details
With 1.4bn population each as of 2017, India and China are the most numerous countries out of the six forming the focus of this report. However, the two countries differ widely in terms of per capita GDP, with that of China being more than twice that ...View more details
India’s is the world’s 10th-largest pharmaceutical market in US dollar terms - with sales of over USD 25bn in 2017 - and the largest generic drug manufacturer and exporter globally. Strong domestic demand and robust exports have ...View more details
In the third quarter of 2018, China’s pharmaceutical and medicine production declined by 28.5% y/y to 573,000 tonnes, In 2018, many pharmaceutical producers were affected by the ongoing reform for new chemical drugs classification system, and ...View more details
Indonesia’s pharmaceutical and healthcare sector is under-developed compared to many other countries in the Association of Southeast Asian Nations (ASEAN). Indonesia has one of the fewest physicians and hospital beds per 1,000 population in the ...View more details
The third quarter of 2018 witnessed a continuous growth of China’s healthcare sector, mostly driven by the online healthcare segment. The growth was attributed to increasing demand for quality healthcare, stimulated by the country’s ...View more details
The Pharmaceuticals & Healthcare sector in the Philippines is in a phase of accelerating growth as strong economic performance in the country has been making healthcare more accessible to Filipinos. Additionally, the Philippines government has ...View more details